Status:
COMPLETED
Intraoperative Carbetocin to Decrease Blood Loss During Hysteroscopic Myomectomy
Lead Sponsor:
Mansoura University Hospital
Conditions:
Myoma;Uterus
Eligibility:
FEMALE
18-45 years
Phase:
PHASE4
Brief Summary
Submucous myomas represent one of the main indications of operative hysteroscopy. Since 1976 when Neuwirth and Amin reported the first five cases of excision of submucous myomas , several techniques h...
Detailed Description
All patients will have preoperative evaluation by gynecologists and anesthetists, with history taking and pelvic examination. A TVS scan will be done to determine the number, size and location of the ...
Eligibility Criteria
Inclusion
- Symptomatic women aged 18-45 years diagnosed by transvaginal sonography (TVS) to have single type 0 or I submucous uterine myomas according to FIGO classification system with a largest diameter ≤ 4 cm and myometrial free margin of at least 10 mm.
Exclusion
- • Age \< 18 or \> 45 years.
- Uterine septum or structural uterine abnormality (including multiple uterine fibroids and/or multiple submucous myomas)
- Present or history of cervical or uterine malignancies.
- Active pelvic infection.
- Chronic medical diseases (cardiopulmonary, thromboembolic, hepatic, or renal diseases).
- Bleeding disorders.
- Patients receiving anticoagulant therapy.
- Patients receiving gonadotropin-releasing hormone (GnRH) analogues.
- History of adverse reaction contraindications for Carbetocin.
Key Trial Info
Start Date :
July 15 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 1 2022
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT04482959
Start Date
July 15 2020
End Date
February 1 2022
Last Update
April 6 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Faculty of Medicine
Al Mansurah, Dakahlia Governorate, Egypt, 050